A Trial of SHR1701 Plus Chemotherapy in Patients With Gastric or Gastroesophageal Cancer
A phase 3 trial of Retlirafusp alfa run by Suzhou Suncadia Biopharmaceuticals Co., Ltd., active.
Overview
A Trial of SHR1701 Plus Chemotherapy in Patients With Gastric or Gastroesophageal Cancer is a phase 3 interventional study registered as NCT04950322 by Suzhou Suncadia Biopharmaceuticals Co., Ltd., with 737 participants enrolled, started 2021-12-06. Conditions listed: Gastric or Gastroesophageal Junction Cancer. No results are recorded here; the registry entry is the source.
Setting
A Randomized, Double-Blind, Multi-Center, Phase III Clinical Study of SHR-1701 Plus Chemotherapy Versus Placebo Plus Chemotherapy as Treatment in Patients With Previously Untreated, Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer
Phase
Phase 3
Sponsor
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Registry
Enrolled
737